Author Correction: Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes

Author Correction: Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes

Saved in:

Bibliographic Details
Main Authors:	Ramandip Grewal, Lena Nguyen, Sarah A. Buchan, Sarah E. Wilson, Sharifa Nasreen, Peter C. Austin, Kevin A. Brown, Deshayne B. Fell, Jonathan B. Gubbay, Kevin L. Schwartz, Mina Tadrous, Kumanan Wilson, Jeffrey C. Kwong
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-12-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-024-55350-3
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pregnancy, fetal, and neonatal outcomes after a first booster dose of covid-19 vaccine during pregnancy in Ontario, Canada: population based, retrospective cohort study
by: Annette K Regan, et al.
Published: (2023-10-01)

Clinical characteristics and booster vaccine effectiveness of the Omicron variant
by: Lijun Sun, et al.
Published: (2024-11-01)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
by: Jianyang Liu, et al.
Published: (2023-12-01)

Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation
by: Sigrun Einarsdottir, et al.
Published: (2024-10-01)

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents
by: Amparo L. Figueroa, et al.
Published: (2025-12-01)

Attitudes and beliefs regarding COVID-19 and COVID-19 Omicron booster vaccine among adults in the vaccine safety datalink, 2022–2023
by: Laura P. Hurley, et al.
Published: (2025-12-01)

A scoping review of active, participant centred, digital adverse events following immunization (AEFI) surveillance of WHO approved COVID-19 vaccines: A Canadian immunization Research Network study
by: Mohamed Serhan, et al.
Published: (2024-12-01)

COVID-19 Vaccine Booster Dose Fails to Enhance Antibody Response to Omicron Variant in Reinfected Healthcare Workers
by: Leire Fernández-Ciriza, et al.
Published: (2025-01-01)

Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough
by: Yichuan Yao, et al.
Published: (2025-01-01)

Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster dosesResearch in context
by: Annalisa Ciabattini, et al.
Published: (2025-03-01)

Association between mRNA COVID-19 vaccine boosters and mortality in Japan: The VENUS study
by: Wataru Mimura, et al.
Published: (2024-12-01)

Role of booster vaccines and hybrid immunity against severe COVID-19 outcomes during BA.5 omicron predominance in Thailand
by: Kannikar Intawong, et al.
Published: (2023-12-01)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
by: Tao Li, et al.
Published: (2023-12-01)

Booster vaccines dose reduced mortality in hospitalized COVID-19 patients requiring oxygen supplementation: Evidence from the Beijing Omicron outbreak
by: Xinrui Wang, et al.
Published: (2024-12-01)

Increase over time of antibody levels 3 months after a booster dose as an indication of better protection against Omicron infection
by: Rea Bingula, et al.
Published: (2023-12-01)

Group B Streptococcus disease during infancy and risk of subsequent neurodevelopmental impairments in young children: a population-based cohort study in Ontario, CanadaResearch in context
by: Romina Fakhraei, et al.
Published: (2025-08-01)

Immunogenicity of ARCT-154, a self-amplifying mRNA COVID-19 vaccine, in different booster settings
by: Yoshiaki Oda, et al.
Published: (2025-08-01)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
by: Minrun Duan, et al.
Published: (2023-12-01)

Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?
by: Paskorn Sritipsukho, et al.
Published: (2023-12-01)

The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern.
by: Carl Graham, et al.
Published: (2022-10-01)

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
by: Camilo C. Roa, et al.
Published: (2024-12-01)

The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells
by: Joel Sop, et al.
Published: (2025-03-01)

Safety of the bivalent COVID-19 mRNA booster vaccination among persons aged over 18 years in the Republic of Korea
by: Seok-Kyoung Choi, et al.
Published: (2024-12-01)

From Wuhan to Omicron K.P2 strain: A comprehensive review of SARS-CoV-2 phylogeny and public health implications of the latest booster vaccine
by: Adewunmi Akingbola, et al.
Published: (2025-12-01)

Elicitation of neutralizing antibodies and IgG4 subclass switching following booster vaccination with ancestral COVID-19 mRNA vaccines does not reduce breakthrough infections
by: Engin Berber, et al.
Published: (2025-12-01)

Differential immunogenicity in people living with HIV with varying CD4 levels after bivalent mRNA COVID-19 booster vaccination
by: Napon Hiranburana, et al.
Published: (2025-01-01)

Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea
by: Mijeong Ko, et al.
Published: (2024-08-01)

Using Vaccine Safety Data to Demonstrate the Potential of Pooled Data Analysis
by: Steven Hawken, et al.
Published: (2024-09-01)

Comparing the protection of heterologous booster of inhaled Ad5-nCoV vaccine and hybrid immunity against Omicron BA.5 infection: a cohort study of hospital staff in China
by: Kai Wang, et al.
Published: (2024-12-01)

COVID-19 travel restrictions and the International Health Regulations (2005)
by: Kumanan Wilson, et al.
Published: (2020-05-01)

Pumping Speed Measurement and Analysis for the Turbo Booster Pump
by: R. Y. Jou, et al.
Published: (2004-01-01)

Effectiveness of CoronaVac primary series with and without booster against hospitalized COVID-19 during the Omicron-predominant epidemic wave in the Philippines: a test-negative case–control study
by: Kristal An Agrupis, et al.
Published: (2025-12-01)

COVID‐19 pandemic and population‐level pregnancy and neonatal outcomes in general population: A living systematic review and meta‐analysis (Update#2: November 20, 2021)
by: Jie Yang, et al.
Published: (2022-03-01)

Circulating Antibodies Against Common Cold Coronaviruses Do Not Interfere with Immune Responses to Primary or Booster SARS-CoV-2 mRNA Vaccines
by: Bindu Adhikari, et al.
Published: (2025-05-01)

Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study
by: María Jesús López, et al.
Published: (2025-12-01)

Longitudinal cellular and humoral immune responses following COVID-19 BNT162b2-mRNA-based booster vaccination of craft and manual workers in Qatar
by: Remy Thomas, et al.
Published: (2025-03-01)

First detection of Omicron variant BA.4.1 lineage in dogs, Chile
by: B. Agüero, et al.
Published: (2024-12-01)

Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trial
by: Shipo Wu, et al.
Published: (2025-08-01)

Effective cellular and neutralizing immunity against SARS-CoV-2 after mRNA booster vaccination is associated with pDC and B cell activation
by: Dorit Fabricius, et al.
Published: (2025-05-01)

Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster
by: Jun Liu, et al.
Published: (2024-04-01)